Invezz is an independent platform with the goal of helping users achieve financial freedom. In order to fund our work, we partner with advertisers who compensate us for users that Invezz refers to their services. While our reviews and assessments of each product on the site are independent and unbiased, brands may pay to appear higher up our table rankings or place ads in specific areas of the site. The order in which products and services appear on Invezz does not represent an endorsement from us, and please be aware that there may be other platforms available to you than the products and services that appear on our website. Read more about how we make money >
Teva Pharmaceutical Industries Limited (TLV:TEVA)
|Dividend Rate (ttm)||0.0000|
|Trading Day||Sep 14|
|Day's Range||29.91 - 29.91|
|52 Week Range||27.38 - 43.9|
Teva Pharmaceutical Industries Limited dividends
Teva- Pharmaceutical Industries Ltd. has a market cap or net worth of ₪32.97 billion. The enterprise value is ₪0.
Teva- Pharmaceutical Industries Ltd. has 1.10 billion shares outstanding.
The trailing PE ratio is 0.0000 and the forward PE ratio is 0.0000. Teva- Pharmaceutical Industries Ltd.'s PEG ratio is 0.0000.
Stock Price Statistics
The stock price has decreased by -0.0209%. The beta is 0.0000, so Teva- Pharmaceutical Industries Ltd.'s price volatility has been lower than the market average.
In the last 12 months, Teva- Pharmaceutical Industries Ltd. had revenue of ₪0 and earned ₪0 in profits. Earnings per share was ₪.
P O B 3190
Teva Pharmaceutical Industries Ltd. has been developing and producing medicines to improve people's lives for more than a century.
It is a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry.
Along with its established presence in generics, it has significant innovative research and operations supporting its growing portfolio of specialty and biopharmaceutical products..